While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized.Multisystem inflammatory syndrome in adults is an emerging entity that has yet to be fully characterized. The syndrome involves extrapulmonary multiorgan failure with hyperinflammation that typically affects young healthy males, approximately 2 to 12 weeks after infection with SARS-CoV-2. There are no formal guidelines for management, although the syndrome appears responsive to immunomodulators and supportive care. Clinicians should be aware of this unusual and severe clinical entity and the general principles of its management.